Items Tagged with 'Alzheimerâs disease'
On January 17, 2012, Medivation, Inc.(NASDAQ: MDVN) and Pfizer Inc. (NYSE: PFE) announced results from the CONCERT trial, which is a Phase 3 trial that evaluated dimebon (latrepirdine) when added to ongoing treatment with donepezil HCL tablets in patients with mild-to-moderate Alzheimer’s disease.
George Putnam has suceessfully invested in distressed companies for nearly 30 years and The Turnaround Letter's market-beating returns demonstrate the profit potential. He knows all the pitfalls, too--which he shares in this free report!
Distressed Investing Blog
We believe that it is very important not to let the market volatility spook you into bailing out of stocks or taking other similar drastic action. While it may be painful to ride out a sharp downturn, that is the best strategy. The market will recover from any of these downdrafts, usually quite quickly.
Your Financial Security is Serious Business...
so why should you trust The Turnaround Letter?
Ranked as #1 Performing Newsletter for 15-Yr. Returns: Turnaround Letter's 12.3% vs. S&P's 2.2%
29+ Years of Turnaround Investing Experience & Reliable Stock Market Advice
Diverse Monthly Stock Picks Personally Selected by George Putnam
2015 Stock Profit
George Putnam's Turnaround Letter has enjoyed market-beating returns for nearly 30 years now and 2015 is no different: 10 of this year's 12 sale recommendations have seen increases--with four of those 100% or higher. Despite recent stock market turbulence, 2015's closed out stock picks have realized an average gain of 69% thus far.
The chart below reflects The Turnaround Letter's past five sale recommendations.
Most Recent Value Stock Returns
Copyright © All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing.